O
BCAB icon

OrbiMed’s BioAtla BCAB Stock Holding History

OrbiMed’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-20,186
Closed -$1.72M – 118
2023
Q3 		$1.72M Sell
20,186
-2,938
-13% -$374K 0.04% 114
2023
Q2 		$3.47M Sell
23,124
-54,096
-70% -$9.3M 0.06% 109
2023
Q1 		$10.3M Buy
77,220
+70,573
+1,062% +$12.7M 0.2% 86
2022
Q4 		$2.74M Buy
+6,647
New +$2.76M 0.05% 100

Other funds holding BCAB

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed's BCAB Position: Q4 2023 in Review

OrbiMed sold out of BioAtla (BCAB) in Q4 2023, closing a stake of 20,186 shares — an estimated $1.72M sold.

OrbiMed first reported a position in BCAB in Q4 2022 and held it in 4 quarters. The position peaked at $10.3M in Q1 2023. 79 funds tracked by Wall St. Rank hold BCAB as of Q4 2023.

  • OrbiMed reported no remaining BioAtla position as of Q4 2023 after selling out during the quarter.
  • OrbiMed sold 20,186 BioAtla shares in Q4 2023, an estimated $1.72M.
  • OrbiMed first reported a position in BioAtla in Q4 2022 and held it in 4 quarters.
  • OrbiMed's BioAtla position peaked at $10.3M in Q1 2023.
  • 79 funds tracked by Wall St. Rank held BioAtla as of Q4 2023.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.